Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA266-0008  |   NCT07293351

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 1/Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 48
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not amenable to curative surgery or radiation therapy) or metastatic Renal Cell Carcinoma (RCC).
    1. Participants must have clear cell RCC (ccRCC) or non-clear cell RCC (nccRCC) may be enrolled in PartNote: Part 2 may only enroll participants with ccRCC.
      1. Participants may have favorable, intermediate or poor risk disease categories.
        1. Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:
          1. One prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
            1. For Part 1A participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received any therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., ipilimumab).
              1. For Part 1B participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with cabozantinib.
              2. Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

                Criterios de exclusión

                Criterios de exclusión Icon
                • Participants must not have any untreated known CNS metastases.
                  1. Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of Cycle 1 Day1 (C1D1).
                    1. Participants must not have a history of interstitial lung disease or pneumonitis.
                      1. Participants must not have an uncontrolled pleural or pericardial effusion requiring recurrent therapeutic drainage procedures.
                        1. Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to C1D1, uncontrolled hypertension (≥ 150 systolic, ≥ 90 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
                          1. Participants must not have a urine protein ≥ 2+ and 24 hour urine protein ≥ 1 g at baseline.
                            1. Participants must not have evidence of major coagulation disorders.
                              1. Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 6 months prior to C1D1.
                                1. Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months.
                                  1. Participants must not have had a major surgery or trauma within 28 days prior to C1D1.
                                    Información Adicional *
                                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                                      Opciones de tratamiento

                                      Brazos del estudio

                                      INTERVENCIÓN ASIGNADA

                                      Brazos del estudio

                                      Experimental: Part 1A: Arm A

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Ipilimumab

                                      Brazos del estudio

                                      Experimental: Part 1A: Arm B

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Ipilimumab

                                      Brazos del estudio

                                      Experimental: Part 1B: Arm G

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Cabozantinib

                                      Brazos del estudio

                                      Experimental: Part 1B: Arm H

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Cabozantinib

                                      Brazos del estudio

                                      Experimental: Part 2A: Arm C

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Ipilimumab

                                      Brazos del estudio

                                      Experimental: Part 2A: Arm D

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Ipilimumab

                                      Brazos del estudio

                                      Other: Part 2A: Arm E

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Ipilimumab, Nivolumab

                                      Brazos del estudio

                                      Experimental: Part 2A: Arm F

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig

                                      Brazos del estudio

                                      Experimental: Part 2B: Arm I

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Cabozantinib

                                      Brazos del estudio

                                      Experimental: Part 2B: Arm J

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig, Cabozantinib

                                      Brazos del estudio

                                      Other: Part 2B: Arm K

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Nivolumab

                                      Brazos del estudio

                                      Experimental: Part 2B: Arm L

                                      INTERVENCIÓN ASIGNADA
                                      • Drug: Pumitamig
                                      Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                                      Verifique su elegibilidad
                                      Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                                      Compatibilizar con un estudio
                                      Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                                      Seleccione una ubicación del centro del estudio
                                      Seleccione una ubicación del centro del estudio que sea conveniente para usted
                                      Registrarse
                                      Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                                      Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias